title: Letter by Rustemi Regarding Article, "Randomized, Open-Label, Phase 1/2a Study to Determine the Maximum Tolerated Dose of Intraventricular Sustained Release Nimodipine for Subarachnoid Hemorrhage (NEWTON [Nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid Hemorrhage])".
authors.affiliation: Department of Neuroscience and Neurosurgery, San Bortolo Hospital, Vicenza, Italy.
authors.forename: Oriela
authors.initials: O
authors.lastname: Rustemi
mesh_terms: D003692:Delayed-Action Preparations; D006801:Humans; D020714:Maximum Tolerated Dose; D009553:Nimodipine; D013345:Subarachnoid Hemorrhage; D014665:Vasodilator Agents; D020301:Vasospasm, Intracranial
chemical_list: D003692:Delayed-Action Preparations; D014665:Vasodilator Agents; D009553:Nimodipine